Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1776 - 1800 of 3565 in total
TZ-101 composes of GDP-L-fucose and fucosyltransferase VI
Investigational
Matched Name: … TZ-101
Matched Description: … TZ-101 composes of [GDP-L-fucose] and fucosyltransferase VI …
Investigational
Matched Name: … APT-101
Matched Salts name: … APT-101 hydrochloride …
ATX-101 (medical), sodium deoxycholate for subcutaneous injection, is being evaluated as a treatment for the reduction of localized fat deposits. This includes treatment of superficial lipomas (benign tumors of soft tissue composed of mature fat cells), fat deposits in the submental region of the face/neck, and localized fat deposits in...
Investigational
Matched Name: … ATX-101
Matched Description: … ATX-101 demonstrates a relative selectivity for fat over other tissues. ... ATX-101 (medical), sodium deoxycholate for subcutaneous injection, is being evaluated as a treatment …
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. As of July...
Investigational
Matched Name: … IMM-101
Matched Description: … IMM-101 is a heat-inactivated immune-activating mycobacterial product. ... Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help …
ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).
Investigational
Matched Name: … ORP-101
Matched Description: … ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Matched Name: … ATG-101
Matched Description: … ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive …
CAM-101 is an allogeneic human platelet lysate product depleted of fibrinogen.
Investigational
Matched Name: … CAM-101
Matched Description: … CAM-101 is an allogeneic human platelet lysate product depleted of fibrinogen. …
MDR-101 is a CD34+ hematopoietic stem and progenitor cells with CD3+ T-cells
Investigational
Matched Name: … MDR-101
Matched Description: … MDR-101 is a CD34+ hematopoietic stem and progenitor cells with CD3+ T-cells …
Investigational
Matched Name: … HUB-101
TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)).
Investigational
Matched Name: … TERN-101
Matched Description: … TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy ... , and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis …
RBIO-101 is a recombinant adeno-associated virus vector encoding human CYP4V2 protein.
Investigational
Matched Name: … RBIO-101
Matched Description: … RBIO-101 is a recombinant adeno-associated virus vector encoding human CYP4V2 protein. …
Investigational
Matched Name: … ACTUS-101
10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).
Investigational
Matched Name: … 10-hydroxycamptothecin …
Matched Description: … 10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in …
WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product
Investigational
Matched Name: … WU-NK-101
Matched Description: … WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product …
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
Matched Name: … SIS-101-ADO …
Matched Description: … SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis …
Investigational
Matched Synonyms: … 3,4,5-piperidinetriol, 2-(hydroxymethyl)-1-(9-methoxynonyl)-, (2r,3r,4r,5s)- …
Matched Name: … N-9-Methoxynonyldeoxynojirimycin …
Matched Iupac: … (2R,3R,4R,5S)-2-(hydroxymethyl)-1-(9-methoxynonyl)piperidine-3,4,5-triol …
Matched Salts name: … N-9-Methoxynonyldeoxynojirimycin hydrochloride …
Experimental
Matched Name: … (9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene …
Matched Iupac: … (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-{[(9R,10R)-10-hydroxy-9,10-dihydrophenanthren-9- …
Experimental
Matched Name: … (9S,10S)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene …
Matched Iupac: … (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-{[(9S,10S)-10-hydroxy-9,10-dihydrophenanthren-9- …
P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
Investigational
Matched Name: … P-BCMA-101
Matched Description: … P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology. …
Experimental
Matched Synonyms: … (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid …
Matched Name: … 9(S)-HODE …
Matched Iupac: … (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid …
Experimental
Matched Name: … 3-{[(9-CYANO-9,10-DIHYDRO-10-METHYLACRIDIN-9-YL)CARBONYL]AMINO}PROPANOIC ACID …
Matched Iupac: … 3-[(9-cyano-10-methyl-9,10-dihydroacridin-9-yl)formamido]propanoic acid …
Experimental
Matched Name: … 10-decarboxymethylaclacinomycin A …
Matched Iupac: … (8S,10S)-10-{[(2R,4S,5S,6S)-4-(dimethylamino)-5-{[(2R,4S,5R,6S)-4-hydroxy-6-methyl-5-{[(2R,6R)-6-methyl …
ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain, itch and visceral pain. Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at...
Investigational
Matched Name: … ADL 10-0101 …
Matched Description: … ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. ... Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment ... Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic …
Experimental
Matched Name: … 9-Deazaguanine …
Experimental
Matched Synonyms: … 9-Hydroxypropyladenine, S-Isomer …
Matched Name: … S-9-(2-hydroxypropyl)adenine …
Matched Iupac: … (2S)-1-(6-amino-9H-purin-9-yl)propan-2-ol …
Displaying drugs 1776 - 1800 of 3565 in total